Milestones in the staging, classification, and biology of Merkel cell carcinoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 9, 2014, Pages 1255-1262

  Moshiri, Ata S ^a,b   Nghiem, Paul ^a,b,c,d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c USA   (United States)

^d SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAPSID PROTEIN; PROTEIN P63;

ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CLINICAL ASSESSMENT; CONSENSUS; EVIDENCE BASED PRACTICE; HUMAN; ICD-10; ICD-9; IMMUNOSUPPRESSIVE TREATMENT; LYMPH VESSEL METASTASIS; MERKEL CELL POLYOMAVIRUS; MERKEL CELL TUMOR; ONCOLOGY; PRIMARY TUMOR; PROTEIN EXPRESSION; RADIATION EXPOSURE; SURVIVAL; TRANSLATIONAL RESEARCH; TUMOR ASSOCIATED LEUKOCYTE; ULTRAVIOLET RADIATION; CARCINOMA, MERKEL CELL; IMMUNOTHERAPY; PRACTICE GUIDELINE; PROGNOSIS;

CARCINOMA, MERKEL CELL; HUMANS; IMMUNOTHERAPY; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS;

EID: 84907288517     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0123     Document Type: Article

References (52)

1. Lemos BD, Storer BE, Iyer JG, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 2010;63:751-761.
2. Lemos B, Nghiem P. Merkel cell carcinoma: more deaths but still no pathway to blame. J Invest Dermatol 2007;127:2100-2103.
3. Heath M, Jaimes N, Lemos B, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol 2008;58:375-381.
4. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008;319:1096-1100.
5. Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer 2010;10:878-889.
6. Yiengpruksawan A, Coit DG, Thaler HT, et al. Merkel cell carcinoma. Prognosis and management. Arch Surg 1991;126:1514-1519.
7. Allen PJ, Zhang ZF, Coit DG. Surgical management of Merkel cell carcinoma. Ann Surg 1999;229:97-105.
8. Allen PJ, Bowne WB, Jaques DP, et al. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol 2005;23:2300-2309.
9. Clark JR, Veness MJ, Gilbert R, et al. Merkel cell carcinoma of the head and neck: is adjuvant radiotherapy necessary? Head Neck 2007;29:249-257.
10. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York, NY: Springer-Verlag; 2002.
11. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
12. Gupta SG, Wang LC, Penas PF, et al. Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: rhe Dana-Farber experience and meta-analysis of the literature. Arch Dermatol 2006;142:685-690.
13. Iyer JG, Koba S, Nghiem P. Toward better management of merkel cell carcinoma using a consensus staging system, new diagnostic codes and a recently discovered virus. Actas Dermosifiliogr 2009;100(Suppl 2):49-54.
14. Popp S, Waltering S, Herbst C, et al. UV-B-type mutations and chromosomal imbalances indicate common pathways for the development of Merkel and skin squamous cell carcinomas. Int J Cancer 2002;99:352-360.
15. Boukamp P. UV-induced skin cancer: similarities - variations. J Dtsch Dermatol Ges 2005;3:493-503.
16. Ullrich SE. Mechanisms underlying UV-induced immune suppression. Mutat Res 2005;571:185-205.
17. Brewer JD, Shanafelt TD, Otley CC, et al. Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study. J Clin Oncol 2012;30:843-849.
18. Engels EA, Frisch M, Goedert JJ, et al. Merkel cell carcinoma and HIV infection. Lancet 2002;359:497-498.
19. Hemminki K, Liu X, Ji J, et al. Kaposi sarcoma and Merkel cell carcinoma after autoimmune disease. Int J Cancer 2012;131:E326-328.
20. Penn I, First MR. Merkel's cell carcinoma in organ recipients: report of 41 cases. Transplantation 1999;68:1717-1721.
21. Rodig SJ, Cheng J, Wardzala J, et al. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest 2012;122:4645-4653.
22. Nicol JT, Robinot R, Carpentier A, et al. Age-specific seroprevalences of merkel cell polyomavirus, human polyomaviruses 6, 7, and 9, and trichodysplasia spinulosa-associated polyomavirus. Clin Vaccine Immunol 2013;20:363-368.
23. Martel-Jantin C, Pedergnana V, Nicol JT, et al. Merkel cell polyomavirus infection occurs during early childhood and is transmitted between siblings. J Clin Virol 2013;58:288-291.
24. DeCaprio JA, Garcea RL. A cornucopia of human polyomaviruses. Nat Rev Microbiol 2013;11:264-276.
25. Houben R, Shuda M, Weinkam R, et al. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol 2010;84:7064-7072.
26. Carter JJ, Paulson KG, Wipf GC, et al. Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma. J Natl Cancer Inst 2009;101:1510-1522.
27. Paulson KG, Carter JJ, Johnson LG, et al. Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res 2010;70:8388-8397.
28. Touze A, Le Bidre E, Laude H, et al. High levels of antibodies against merkel cell polyomavirus identify a subset of patients with merkel cell carcinoma with better clinical outcome. J Clin Oncol 2011;29:1612-1619.
29. Andea AA, Coit DG, Amin B, Busam KJ. Merkel cell carcinoma: histologic features and prognosis. Cancer 2008;113:2549-2558.
30. Ng L, Beer TW, Murray K. Vascular density has prognostic value in Merkel cell carcinoma. Am J Dermatopathol 2008;30:442-445.
31. Fields RC, Busam KJ, Chou JF, et al. Five hundred patients with Merkel cell carcinoma evaluated at a single institution. Ann Surg 2011;254:465-473.
32. Kukko HM, Koljonen VS, Tukiainen EJ, et al. Vascular invasion is an early event in pathogenesis of Merkel cell carcinoma. Mod Pathol 2010;23:1151-1156.
33. Paulson KG, Iyer JG, Blom A, et al. Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J Invest Dermatol 2013;133:642-646.
34. Johnson ME, Zhu F, Li T, et al. Absolute lymphocyte count: a potential prognostic factor for Merkel cell carcinoma. J Am Acad Dermatol 2014;70:1028-1035.
35. Paulson KG, Iyer JG, Tegeder AR, et al. Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol 2011;29:1539-1546.
36. Sihto H, Bohling T, Kavola H, et al. Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a population-based study. Clin Cancer Res 2012;18:2872-2881.
37. Afanasiev OK, Yelistratova L, Miller N, et al. Merkel polyomavirusspecific T cells fluctuate with Merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res 2013;19:5351-5360.
38. Lipson EJ, Vincent JG, Loyo M, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus, and overall survival. Cancer Immunology Research 2013;1:54-63.
39. Veness MJ, Perera L, McCourt J, et al. Merkel cell carcinoma: improved outcome with adjuvant radiotherapy. ANZ J Surg 2005;75:275-281.
40. Foote M, Veness M, Zarate D, Poulsen M. Merkel cell carcinoma: the prognostic implications of an occult primary in stage IIIB (nodal) disease. J Am Acad Dermatol 2012;67:395-399.
41. Deneve JL, Messina JL, Marzban SS, et al. Merkel cell carcinoma of unknown primary origin. Ann Surg Oncol 2012;19:2360-2366.
42. Chen KT, Papavasiliou P, Edwards K, et al. A better prognosis for Merkel cell carcinoma of unknown primary origin. Am J Surg 2013;206:752-757.
43. Tarantola TI, Vallow LA, Halyard MY, et al. Unknown primary Merkel cell carcinoma: 23 new cases and a review. J Am Acad Dermatol 2013;68:433-440.
44. Yao JY, Chen JK. Roles of p63 in epidermal development and tumorigenesis. Biomed J 2012;35:457-463.
45. Asioli S, Righi A, de Biase D, et al. Expression of p63 is the sole independent marker of aggressiveness in localised (stage I-II) Merkel cell carcinomas. Mod Pathol 2011;24:1451-1461.
46. Hall BJ, Pincus LB, Yu SS, et al. Immunohistochemical prognostication of Merkel cell carcinoma: p63 expression but not polyomavirus status correlates with outcome. J Cutan Pathol 2012;39:911-917.
47. Stetsenko GY, Malekirad J, Paulson KG, et al. p63 Expression in Merkel cell carcinoma predicts poorer survival yet may have limited clinical utility. Am J Clin Pathol 2013;140:838-844.
48. Bichakjian CK, Olencki T, Alam M, et al. NCCN Clinical Practice Guidelines in Oncology: Merkel Cell Carcinoma. Version 1, 2014. Available at: NCCN.org. Accessed July 30, 2014.
49. Miller NJ, Bhatia S, Parvathaneni U, et al. Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma. Curr Treat Options Oncol 2013;14:249-263.
50. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.
51. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
52. Fisher TS, Kamperschroer C, Oliphant T, et al. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother 2012;61:1721-1733.